Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Chinook Therapeutics Inc (KDNY) USD0.0001

Sell:$16.37 Buy:$16.51 Change: $1.08 (7.01%)
NASDAQ:0.99%
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Sell:$16.37
Buy:$16.51
Change: $1.08 (7.01%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Sell:$16.37
Buy:$16.51
Change: $1.08 (7.01%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Chinook Therapeutics, Inc., formerly Aduro Biotech, Inc., is a clinical-stage biotechnology company. The Company develops precision medicines for kidney diseases. The Company’s products focus on severe chronic kidney disorders. The Company assembled a portfolio of precision medicines product candidates designed to address severe chronic kidney diseases. Its development programs consist of atrasentan, BION-1301 and CHK-336. Atrasentan, a potent and selective endothelin receptor antagonist that the Company is developing for treatment of primary glomerular diseases, including IgAN. IgAN is a serious progressive autoimmune disease of the kidney. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase 1b trial for IgA nephropathy. CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other chronic kidney diseases, including polycystic kidney disease.

Contact details

Address:
1600 FAIRVIEW AVE E.
SEATTLE
98102
United States
Telephone:
+1 (206) 4857051
Website:
www.aduro.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KDNY
ISIN:
US16961L1061
Market cap:
$649.66 million
Shares in issue:
42.16 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Eric Dobmeier
    President, Chief Executive Officer, Director
  • Eric Bjerkholt
    Chief Financial Officer
  • Tom Frohlich
    Chief Business Officer
  • Alan Glicklich
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.